search
Back to results

Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement

Primary Purpose

Pelvic Organ Prolapse

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
EndoFast Reliant™ system for Pelvic Organ Prolapse repair
Sponsored by
Endogun Medical Systems Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pelvic Organ Prolapse

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female aged between 40-80 years (inclusive) who is not pregnant or planning to have further births.
  • Subject suffers from Pelvic Organ Prolapse confirmed by vaginal inspection.
  • Patient under reliable form of contraceptive measure or menopausal.
  • Subject able to comprehend procedure and has signed Informed Consent Form for participation in this study.
  • Subject able to complete the applicable questionnaires.

Exclusion Criteria:

  • Planned to undergo hysterectomy.
  • Uterine prolapse equal to or greater than 3rd degree.
  • Documented Stress Urinary Incontinence on physical examination with full bladder or during complete urodynamic assessment with and without prolapse reduction.
  • Any chronic active and uncontrolled disease.
  • Vaginal bleeding disorders.
  • Needing emergency surgery.
  • Any acute disease.
  • Blood clotting disorders and/or anticoagulant treatment.
  • Known cognitive or psychiatric disorder.
  • High operative risk.
  • Any ongoing malignant disease.
  • Concurrent participation in any other clinical trial

Sites / Locations

  • CHU de Caen
  • Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique
  • Sheba Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

I

Arm Description

Use of EndoFast Reliant System

Outcomes

Primary Outcome Measures

Safety is defined as paucity of major device-related complications.

Secondary Outcome Measures

Performance as defined by relative improvement in Pelvic Organ Prolapse staging (as reported post operatively versus preoperatively) using the POPQ grading system.

Full Information

First Posted
March 12, 2007
Last Updated
November 18, 2009
Sponsor
Endogun Medical Systems Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT00446693
Brief Title
Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement
Official Title
A Single Arm, Multi-center, Prospective Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement
Study Type
Interventional

2. Study Status

Record Verification Date
November 2009
Overall Recruitment Status
Completed
Study Start Date
February 2007 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Endogun Medical Systems Ltd.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to clinically assess the safety and performance of the EndoFast Reliant™ system as a less invasive treatment for Pelvic Organ Prolapse.
Detailed Description
Background: Pelvic Organ Prolapse represents a significant problem worldwide and may have a significant negative impact on a woman's quality of life. The uterus, rectum and the bladder are held in their normal positions just above the inner end of the vagina by a "hammock" made up of supportive muscles and ligaments. Wear and tear on these supportive structures in the pelvis can allow the uterus, the bladder, the bowels, the vaginal vault or the rectum to sag through the muscle and ligament layers. When this occurs, the rectum, uterus, bowels or bladder can create a bulge into the vagina. In severe cases, it is possible for the sagging rectum, uterus, bowels or bladder to work its way down far enough that the bulge can appear at the vagina's opening or even protrude from the opening. Pelvic Organ Prolapse causes significant discomfort to the patients being associated with urinary incontinence, voiding difficulty culminating with urinary retention, constipation, pain during sexual intercourse, local discomfort, etc. Treatment Options When symptoms occur, many patients initially opt for conservative treatment. Pelvic exercises and vaginal support are the current mainstays of non surgical management. In addition, patients who are poor surgical candidates or are strongly disinclined to surgery can be offered vaginal support (pessaries) for symptom relief. Topical estrogen is an important adjunct in the conservative management of patients with Pelvic Organ Prolapse. However, the primary management strategy for severe Pelvic Organ Prolapse is surgical. The exact treatment choice will depend on the severity of the prolapse and whether there are any related pelvic floor defects. Endogun Medical Systems Ltd. has developed an innovative, minimally-invasive system for repair of Pelvic Floor Prolapse. The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with a proprietary system comprised of a mesh and soft tissue fasteners in a minimally-invasive way. The fasteners can be deployed easily and swiftly in narrow spaces into soft tissue and can support substantially more weight than needed for Pelvic Organ Prolapse repair. Following many pre-clinical tests, the EndoFast Reliant™ system is now available for clinical evaluation. The objective of this study is to evaluate the safety and performance of the EndoFast Reliant™ system for treatment of Pelvic Organ Prolapse. In particular: The study's primary goal is to clinically assess the safety of the EndoFast Reliant™ as a minimally-invasive procedure for vaginal wall reinforcement. The study's secondary goal is to clinically evaluate the performance of the EndoFast Reliant™ system as a minimally-invasive procedure for vaginal wall reinforcement by evaluating the improvement in Pelvic Organ Prolapse using the POPQ grading system. Study Procedures and Follow up: Pre-treatment tests and inspection will be performed within 4 months prior to surgery. Approximately two weeks, three months and six months after the surgery the patient will be invited for physician examination and laboratory tests. Additional Study Measures: In addition to the endpoint parameters, the following study measures will be collected: Symptoms relief and Quality of Life (QOL) considerations. Sexual Function considerations, as documented using the Female Sexual Function (FSFI) questionnaire; Assessment of the physician's satisfaction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pelvic Organ Prolapse

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
I
Arm Type
Experimental
Arm Description
Use of EndoFast Reliant System
Intervention Type
Device
Intervention Name(s)
EndoFast Reliant™ system for Pelvic Organ Prolapse repair
Intervention Description
The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
Primary Outcome Measure Information:
Title
Safety is defined as paucity of major device-related complications.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Performance as defined by relative improvement in Pelvic Organ Prolapse staging (as reported post operatively versus preoperatively) using the POPQ grading system.
Time Frame
12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female aged between 40-80 years (inclusive) who is not pregnant or planning to have further births. Subject suffers from Pelvic Organ Prolapse confirmed by vaginal inspection. Patient under reliable form of contraceptive measure or menopausal. Subject able to comprehend procedure and has signed Informed Consent Form for participation in this study. Subject able to complete the applicable questionnaires. Exclusion Criteria: Planned to undergo hysterectomy. Uterine prolapse equal to or greater than 3rd degree. Documented Stress Urinary Incontinence on physical examination with full bladder or during complete urodynamic assessment with and without prolapse reduction. Any chronic active and uncontrolled disease. Vaginal bleeding disorders. Needing emergency surgery. Any acute disease. Blood clotting disorders and/or anticoagulant treatment. Known cognitive or psychiatric disorder. High operative risk. Any ongoing malignant disease. Concurrent participation in any other clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Von Theobald, Prof.
Organizational Affiliation
Professeur d'Université-Praticien Hospitalier, gynécologie
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michel Cosson, Prof.
Organizational Affiliation
Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Genadi Bitman, MD
Organizational Affiliation
Sheba Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Caen
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique
City
Lille
ZIP/Postal Code
56037
Country
France
Facility Name
Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
52621
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement

We'll reach out to this number within 24 hrs